title: Congenital adrenal hyperplasia: Treatment and outcomes.
abstract: Congenital adrenal hyperplasia (CAH) describes a group of autosomal recessive disorders where there is impairment of cortisol biosynthesis. CAH due to 21-hydroxylase deficiency accounts for 95% of cases and shows a wide range of clinical severity. Glucocorticoid and mineralocorticoid replacement therapies are the mainstays of treatment of CAH. The optimal treatment for adults with CAH continues to be a challenge. Important long-term health issues for adults with CAH affect both men and women. These issues may either be due to the disease or to steroid treatment and may affect final height, fertility, cardiometabolic risk, bone metabolism, neuro-cognitive development and the quality-of-life. Patients with CAH should be regularly followed-up from childhood to adulthood by multidisciplinary teams who have knowledge of CAH. Optimal replacement therapy, close clinical and laboratory monitoring, early life-style interventions, early and regular fertility assessment and continuous psychological management are needed to improve outcome.
authors.affiliation: Department of Endocrinology, Hedi Chaker Hospital, Sfax, Tunisia.
authors.forename: Mahdi
authors.initials: M
authors.lastname: Kamoun
authors.forename: Mouna Mnif
authors.initials: MM
authors.lastname: Feki
authors.forename: Mohamed Habib
authors.initials: MH
authors.lastname: Sfar
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abid
keywords: Bone health; cardio-metabolic risk; congenital adrenal hyperplasia; fertility; final height; glucocorticoids; neurocognitive outcome; quality-of-life